Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

843 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.
Alvarez-Twose I, Martínez-Barranco P, Gotlib J, García-Montero A, Morgado JM, Jara-Acevedo M, Merker JD, Peñalver FJ, Matito A, Hou Y, Sánchez-Muñoz L, Mayado A, Mollejo M, Escribano L, Orfao A. Alvarez-Twose I, et al. Among authors: orfao a. Leukemia. 2016 Aug;30(8):1753-6. doi: 10.1038/leu.2016.30. Epub 2016 Feb 15. Leukemia. 2016. PMID: 26876592 No abstract available.
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.
Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, Muñiz C, Jara-Acevedo M, Álvarez-Twose I, Sanchez-Muñoz L, Matarraz S, Caldas C, Muñoz-González JI, Escribano L, Orfao A. Mayado A, et al. Among authors: orfao a. Leukemia. 2016 Jan;30(1):124-30. doi: 10.1038/leu.2015.176. Epub 2015 Jul 8. Leukemia. 2016. PMID: 26153655
Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L, Matito A, Jara-Acevedo M, Teodosio C, García-Montero A, Morgado JM, Orfao A, Escribano L. Alvarez-Twose I, et al. Among authors: orfao a. Int Arch Allergy Immunol. 2012;157(3):275-80. doi: 10.1159/000329856. Epub 2011 Oct 28. Int Arch Allergy Immunol. 2012. PMID: 22042301 Clinical Trial.
Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis.
Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, Morgado JM, Matito A, Torrelo A, Jaén P, Schwartz LB, Orfao A, Escribano L. Alvarez-Twose I, et al. Among authors: orfao a. Allergy. 2012 Jun;67(6):813-21. doi: 10.1111/j.1398-9995.2012.02812.x. Epub 2012 Mar 28. Allergy. 2012. PMID: 22458675 Free PMC article.
Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I, Morgado JM, Sánchez-Muñoz L, García-Montero A, Mollejo M, Orfao A, Escribano L. Alvarez-Twose I, et al. Among authors: orfao a. Int J Lab Hematol. 2012 Oct;34(5):445-60. doi: 10.1111/j.1751-553X.2012.01427.x. Epub 2012 May 3. Int J Lab Hematol. 2012. PMID: 22551157 Review.
Anaphylaxis as a clinical manifestation of clonal mast cell disorders.
Matito A, Alvarez-Twose I, Morgado JM, Sánchez-Muñoz L, Orfao A, Escribano L. Matito A, et al. Among authors: orfao a. Curr Allergy Asthma Rep. 2014 Aug;14(8):450. doi: 10.1007/s11882-014-0450-8. Curr Allergy Asthma Rep. 2014. PMID: 24947681 Review.
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P. Arock M, et al. Among authors: orfao a. Leukemia. 2015 Jun;29(6):1223-32. doi: 10.1038/leu.2015.24. Epub 2015 Feb 4. Leukemia. 2015. PMID: 25650093 Free PMC article. Review.
843 results